Mature survival (OS) data of a randomised international phase II trial (Jasint1) : vinflunine (VFL) –gemcitabine (GEM) vs. VFL-CBDCA in CDDP-unfit patients (PTS) with advanced urothelial carcinoma (UC)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.